Eli Rosenbaum

Petah Tiqwa, M, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

Journal: The New England journal of medicine

Published: July 22, 2026

Intermediate-term oncological and functional outcomes of neoadjuvant 177-Lu-PSMA-I&T radionuclide treatment followed by radical prostatectomy.

Intermediate-term oncological and functional outcomes of neoadjuvant 177-Lu-PSMA-I&T radionuclide treatment followed by radical prostatectomy.

Journal: World journal of urology

Published: December 01, 2025

Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.

Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.

Journal: International journal of radiation oncology, biology, physics

Published: January 30, 2025

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.

Journal: JAMA network open

Published: January 22, 2025

Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials.

Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials.

Journal: Clinical genitourinary cancer

Published: September 06, 2024

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

Journal: European urology

Published: August 30, 2024

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.

Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.

Journal: Nutrients

Published: July 02, 2023

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2023

A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy.

A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy.

Journal: Frontiers in medicine

Published: May 12, 2023

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors.

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors.

Journal: JAMA network open

Published: February 23, 2023

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.

Journal: Frontiers in oncology

Published: January 27, 2023

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 14, 2022

Showing 1-12 of 48

Last Updated: 09/26/2026